{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T07:18:26Z","timestamp":1788679106178,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Southeast Asia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.lansea.2025.100612","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T15:01:52Z","timestamp":1749135712000},"page":"100612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Outcomes of children with juvenile idiopathic arthritis receiving biological disease-modifying anti-rheumatic drugs: a retrospective single-centre experience from India"],"prefix":"10.1016","volume":"38","author":[{"given":"Pavneet","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farheen","family":"Kizhakkeveettil Saheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bala Siva","family":"Rama Krishna J","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banoth","family":"Sreeshanth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayisha","family":"Kavil Peedika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bareddy Sai","family":"Thrisha Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish Datt","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Lodha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil Kumar","family":"Kabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8004-0536","authenticated-orcid":false,"given":"Narendra","family":"Bagri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lansea.2025.100612_bib2","first-page":"260","article-title":"Biologicals in juvenile idiopathic arthritis","volume":"53","author":"Saini","year":"2016","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.lansea.2025.100612_bib3","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/1756-185X.14813","article-title":"New classification criteria for juvenile idiopathic arthritis","volume":"26","author":"Chen","year":"2023","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"10.1016\/j.lansea.2025.100612_bib4","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1093\/rheumatology\/keab641","article-title":"Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries","volume":"61","author":"Kearsley-Fleet","year":"2022","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.lansea.2025.100612_bib5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.lansea.2025.100612_bib6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.lansea.2025.100612_bib7","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of Tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lansea.2025.100612_bib8","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2665-9913(20)30025-4","article-title":"Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study","volume":"2","author":"Kearsley-Fleet","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.lansea.2025.100612_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12969-023-00897-6","article-title":"Biologic switching patterns among children with non-systemic juvenile idiopathic arthritis","volume":"21","author":"Pedersen","year":"2023","journal-title":"Pediatr Rheumatol"},{"issue":"7","key":"10.1016\/j.lansea.2025.100612_bib10","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00296-022-05108-1","article-title":"Evaluation of flare rate and reduction strategies for bDMARDs in juvenile idiopathic arthritis: real world data from a single-centre cohort","volume":"42","author":"Garc\u00eda-Fern\u00e1ndez","year":"2022","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.lansea.2025.100612_bib11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13075-021-02492-0","article-title":"Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis","volume":"23","author":"Klotsche","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.lansea.2025.100612_bib12","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/acr.23435","article-title":"Flares after withdrawal of biologic therapies in juvenile idiopathic arthritis: clinical and laboratory correlates of remission duration","volume":"70","author":"Simonini","year":"2018","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.lansea.2025.100612_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12969-022-00769-5","article-title":"Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors","volume":"20","author":"Gieling","year":"2022","journal-title":"Pediatr Rheumatol"},{"issue":"5","key":"10.1016\/j.lansea.2025.100612_bib14","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1093\/rheumatology\/keac463","article-title":"Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis","volume":"62","author":"Kearsley-Fleet","year":"2023","journal-title":"Rheumatology (Oxf)"},{"key":"10.1016\/j.lansea.2025.100612_bib15","series-title":"The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis","author":"\u00c7akan","year":"2019"},{"issue":"1","key":"10.1016\/j.lansea.2025.100612_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13075-020-02167-2","article-title":"Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee","volume":"22","author":"Giancane","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.lansea.2025.100612_bib18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3899\/jrheum.2023-0783","article-title":"Clinical characteristics of adolescents with juvenile idiopathic arthritis transitioning to adult rheumatology care in Canada: results from the CAPRI registry","volume":"51","author":"Semalulu","year":"2024","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lansea.2025.100612_bib19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jpeds.2018.08.065","article-title":"Risk of serious infections associated with biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analyses","volume":"204","author":"Aeschlimann","year":"2019","journal-title":"J Pediatr"},{"issue":"12","key":"10.1016\/j.lansea.2025.100612_bib20","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s13312-022-2661-8","article-title":"Conception of national biologics registry for pediatric rheumatology: need of the hour and the way forward","volume":"59","author":"Bagri","year":"2022","journal-title":"Indian Pediatr"},{"issue":"3","key":"10.1016\/j.lansea.2025.100612_bib22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/rheumatology\/kep347","article-title":"Juvenile idiopathic arthritis: improved outcome requires improved access to care","volume":"49","author":"Foster","year":"2010","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.lansea.2025.100612_bib23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40272-023-00594-7","article-title":"Scope of JAK inhibitors in children: recent evidence and way forward","volume":"25","author":"Bagri","year":"2023","journal-title":"Pediatr Drugs"}],"container-title":["The Lancet Regional Health - Southeast Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772368225000836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772368225000836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:30:31Z","timestamp":1762644631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772368225000836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":20,"alternative-id":["S2772368225000836"],"URL":"https:\/\/doi.org\/10.1016\/j.lansea.2025.100612","relation":{},"ISSN":["2772-3682"],"issn-type":[{"value":"2772-3682","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of children with juvenile idiopathic arthritis receiving biological disease-modifying anti-rheumatic drugs: a retrospective single-centre experience from India","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Southeast Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lansea.2025.100612","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100612"}}